Roger Belizaire

This study demonstrates that activating CBL ubiquitin ligase via engineered mutants or small molecules can downregulate tyrosine kinase signaling by enhancing substrate ubiquitination and reducing downstream signaling.

This paper discovers and characterizes SH6, a small molecule degrader of ZBTB7A that increases fetal hemoglobin expression in erythroid cells and shows therapeutic potential for β-hemoglobinopathies.

This study identifies TTLL4 as a therapeutic target in NPM1-mutated AML by showing its role in stabilizing NPM1c and promoting differentiation block, with a small molecule inhibitor demonstrating efficacy.